Novel anticancer agent, benzyldihydroxyoctenone, isolated from Streptomyces sp. causes G1 cell cycle arrest and induces apoptosis of HeLa cells

Cancer Science

Volumn 98, Issue 6, 2007, Pages 795-802

  Lee, Chul Hoon ^a   Lim, Haeyoung ^a   Moon, Sangik ^b   Shin, Choonshik ^b   Kim, Seunghyun ^b   Kim, Bum Joon ^c   Lim, Yoongho ^b  

^a Hanyang University   (South Korea)

^b Konkuk University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 6,8 DIHYDROXYOCT 2 EN 4 ONE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; CYTOCHROME C; DNA FRAGMENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BACTERIUM CULTURE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HT29; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; FIBROBLAST; FLOW CYTOMETRY; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; LYMPHOCYTE; MASS SPECTROMETRY; MOLECULAR MODEL; NICK END LABELING; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STREPTOMYCES; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; G1 PHASE; HELA CELLS; HUMANS; OCTANOLS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; STREPTOMYCES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247877813     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00473.x     Document Type: Article

References (38)

1. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-95.
2. Lokich JJ. Clinical Cancer Medicine: Treatment Tactics. Boston, USA: G. J. Hall Press, 1980: 1-15.
3. Hunter T, Pines J. Cyclins and cancer. Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-82.
4. King RW, Jackson PK, Kirschner MW. Mitosis in transition. Cell 1994; 79: 563-71.
5. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18: 753-61.
6. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059-65.
7. Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 1997; 17: 5771-83.
8. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-30.
9. Guadagno TM, Newport JW. Cdk2 kinase is required for entry into mitosis as a positive regulator of cdc2-cyclin B kinase activity. Cell 1996; 84: 73-82.
10. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
11. Harper JW, Elledge SJ. Cdk inhibitor in development and cancer. Curr Opin Genet Dev 1996; 6: 56-64.
12. Polyak K, Lee MH, Erdjument-Bromage H et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
13. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1 phase progression. Genes Dev 1999; 13: 1501-12.
14. Sharpless NE, DePinho RA. p53: Good cop/bad cop. Cell 2002; 110: 9-12.
15. Lim H, Kim M, Lim Y et al. Inhibition of cell-cycle progression in HeLa cells by HY52, a novel cyclin-dependent kinase inhibitor isolated from Bauhinia forficate. Cancer Lett 2006; 233: 89-97.
16. Lim H, Lim Y, Cho Y et al. Induction of apoptosis in the HepG2 Cells by HY53, a novel natural compound isolated from Bauhinia forficate. J Microbiol Biotechnol 2006; 16: 1262-8.
17. Park H, Kim M, Moon S et al. Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway. Cancer Sci 2006; 97: 430-6.
18. Dubrez L, Goldwasser F, Genne P, Pomier Y, Solary E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995; 9: 1013-24.
19. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999; 96: 245-54.
20. Yang H, Kang K, Lim Y. NMR study of a novel pentasaccharide isolated from Penicillium citrium. Magn Reson Chem 2003; 41: 223-6.
21. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-32.
22. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
23. Dumaz N, Meek DW. Serine 15 phosphorylation stimulates p53 transactivation but dose not directly influence interaction with HDM2. EMBO J 1999; 18: 7002-10.
24. Dantzer F, Schreiber V, Niedergang C et al. Involvement of poly (ADP-ribose) polymerase in base excision repair. Biochimie 1999; 81: 69-75.
25. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
26. Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ. Posttranslational N-myristoylation of Bid as a molecular switch for targeting mitochondria and apoptosis. Science 2000; 290: 1761-5.
27. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92: 4507-11.
28. Stobel T, Swanson L, Korsmeyer S, Cannistra SA. Bax enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 1996; 90: 14 094-9.
29. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyrt DD. The release of cytochrome c from mitochondria: A primary site for Bcl-regulation of apoptosis. Science 1997; 275: 1132-6.
30. 1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
31. Green DR. Apoptotic pathway: The roads to ruin. Cell 1998; 94: 695-8.
32. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-8.
33. Stennicke HR, Salvesen GS. Properties of the caspases. Biochim Biophys Acta 1998; 1387: 17-31.
34. Stennicke HR, Jurgensmeier JM, Shin H et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998; 273: 27 084-90.
35. Scaffidi C, Fulda S, Srinivasan A et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-87.
36. Slee EA, Harte MT, Kluck RM et al. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspase-2,-3,-6,-7,-8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999; 144: 281-92.
37. Wieder T, Essmann F, Prokop A et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001; 97: 1378-87.
38. Saleh HA, Jackson H, Khatib G, Banerjee M. Correlation of Bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia. Pathol Oncol Res 1999; 5: 273-9.